{"entity":{"id":"nsabp-foundation","kind":"company","name":"NSABP Foundation","aka":["National Surgical Adjuvant Breast and Bowel Project","NSABP"],"tldr":"The legacy US surgical adjuvant trials group that proved lumpectomy equals mastectomy, tamoxifen prevents breast cancer and trastuzumab cures more HER2-positive disease.","summary":"Founded in 1958 and led for decades by Bernard Fisher, the NSABP ran the trials that rewrote breast cancer surgery and adjuvant therapy: B-04 and B-06 showed breast conservation equals mastectomy, B-14 and B-20 provided the samples that validated the Oncotype DX recurrence score, P-1 showed tamoxifen prevents breast cancer, B-31 (with NCCTG N9831) established adjuvant trastuzumab, and B-32 validated sentinel node biopsy. It also ran colorectal adjuvant trials (C-series). NSABP merged with RTOG and GOG into NRG Oncology in 2014; the NSABP Foundation continues industry-partnered trials such as KATHERINE (with the German Breast Group) and the neoadjuvant B-series.","asOf":"2026-09-09","links":[{"label":"NSABP Foundation","url":"https://www.nsabp.org"}],"tags":["cooperative-group"],"related":["trastuzumab","trastuzumab-emtansine","oncotype-dx"],"cancers":["breast-hr-positive","breast-her2-positive","colorectal"],"sections":["surgery","prevention"],"technologies":["sentinel-node","endocrine-therapy","chemoprevention"],"targets":[],"drugs":[],"companies":["nrg-oncology","gbg"],"institutions":["nci"],"pathways":[],"terms":[],"trials":["hera-b31-n9831","katherine"],"people":["norman-wolmark","priya-rastogi"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["B-04 / B-06 (breast conservation)","P-1 (tamoxifen prevention)","B-31 (adjuvant trastuzumab)","KATHERINE (with GBG)","Oncotype DX validation (B-14, B-20)"],"provenance":{"editedBy":"OnCo cooperative groups migration (row 251: institution consortium records moved to cooperative-group companies)","editedOn":"2026-09-25"},"hq":"Pittsburgh, PA","country":"US","companyType":"cooperative-group","website":"https://www.nsabp.org","founded":1958,"investors":[],"funding":[]},"route":"/companies/nsabp-foundation/","neighbours":{"drug":[{"id":"oncotype-dx","kind":"drug","name":"Oncotype DX","route":"/drugs/oncotype-dx/"},{"id":"trastuzumab","kind":"drug","name":"Trastuzumab","route":"/drugs/trastuzumab/"},{"id":"trastuzumab-emtansine","kind":"drug","name":"Trastuzumab emtansine","route":"/drugs/trastuzumab-emtansine/"}],"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"},{"id":"breast-her2-positive","kind":"cancer","name":"HER2-positive breast cancer","route":"/cancers/breast-her2-positive/"},{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/"}],"section":[{"id":"prevention","kind":"section","name":"Prevention & Risk","route":"/fronts/prevention/"},{"id":"surgery","kind":"section","name":"Surgery & Interventional","route":"/fronts/surgery/"}],"technology":[{"id":"chemoprevention","kind":"technology","name":"Chemoprevention & risk-reducing surgery","route":"/technologies/chemoprevention/"},{"id":"endocrine-therapy","kind":"technology","name":"Endocrine therapy (SERMs, AIs, SERDs)","route":"/technologies/endocrine-therapy/"},{"id":"sentinel-node","kind":"technology","name":"Sentinel lymph node biopsy","route":"/technologies/sentinel-node/"}],"company":[{"id":"gbg","kind":"company","name":"German Breast Group (GBG)","route":"/companies/gbg/"},{"id":"nrg-oncology","kind":"company","name":"NRG Oncology","route":"/companies/nrg-oncology/"}],"institution":[{"id":"nci","kind":"institution","name":"National Cancer Institute (NIH)","route":"/institutions/nci/"}],"trial":[{"id":"hera-b31-n9831","kind":"trial","name":"HERA, NSABP B-31 & NCCTG N9831 (adjuvant trastuzumab)","route":"/trials/hera-b31-n9831/"},{"id":"katherine","kind":"trial","name":"KATHERINE","route":"/trials/katherine/"},{"id":"nsabp-b04","kind":"trial","name":"NSABP B-04","route":"/trials/nsabp-b04/"},{"id":"nsabp-b06","kind":"trial","name":"NSABP B-06","route":"/trials/nsabp-b06/"},{"id":"nsabp-b32","kind":"trial","name":"NSABP B-32","route":"/trials/nsabp-b32/"},{"id":"nsabp-b51","kind":"trial","name":"NSABP B-51 / RTOG 1304","route":"/trials/nsabp-b51/"},{"id":"nct00268463","kind":"trial","name":"Oxaliplatin and Capecitabine With or Without an Hepatic Arterial Infusion With Floxuridine in Treating Patients Who Are Undergoing Surgery and/or Ablation for Liver Metastases Due to Colorectal Cancer","route":"/trials/nct00268463/"}],"person":[{"id":"norman-wolmark","kind":"person","name":"Norman Wolmark","route":"/people/norman-wolmark/"},{"id":"priya-rastogi","kind":"person","name":"Priya Rastogi","route":"/people/priya-rastogi/"}]}}